More Than a Third of High-Risk Leukemia Patients Respond to an Experimental New Drug

A new drug for patients with acute myeloid leukemia marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

http://www.newswise.com/articles/view/597047/?sc=rsla&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+NewswiseLatestNews+%28Newswise%3A+Latest+News%29